- Home
- DLTH vs HURA Comparison
DLTH vs HURA Comparison
Compare DLTH & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLTH | HURA |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 131.8M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | DLTH | HURA |
|---|---|---|
| Price | $2.94 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $11.50 |
| AVG Volume (30 Days) | 79.2K | ★ 447.0K |
| Earning Date | 12-16-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $602,746,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $0.97 |
| 52 Week High | $4.66 | $5.99 |
Technical Indicators
Market Signals| Indicator | DLTH | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 25.42 |
| Support Level | $2.86 | $0.97 |
| Resistance Level | $3.57 | $2.02 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 7.04 | 4.47 |
Price Performance
Historical ComparisonAbout DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.